Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-03-08, Stock:NVS, The news for the past five days is as follows:
2019-03-01: NEWS1: Novartis AG (NVS) Ex-Dividend Date Scheduled for March 04, 2019.NEWS2: Novartis AG (NVS) Ex-Dividend Date Scheduled for March 04, 2019.NEWS3: Novartis’ CEO is “un-bossing” his 125,000 employees.
2019-03-04: NEWS1: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates.
2019-03-05: NEWS1: FDA&apos;s Scott Gottlieb Resigns — What&apos;s Next For Biotech, Pharma?.NEWS2: Novartis has no plans to sell Sandoz - chairman.NEWS3: The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings.
2019-03-06: NEWS1: The Roche Merger Will Do Wonders for Spark Stock.NEWS2: The Roche Merger Will Do Wonders for Spark Stock.NEWS3: Here's Why Ligand Pharmaceuticals Is Having a Bad Day.NEWS4: Here's Why Ligand Pharmaceuticals Is Having a Bad Day.NEWS5: Novartis or BMY: Who’s Expected to Report Faster EPS Growth?.NEWS6: NVS or BMY: Who’s Expected to Post Faster Revenue Growth in 2019?.NEWS7: Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT.NEWS8: Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT.NEWS9: What Analysts Are Recommending for Novartis and BMY.NEWS10: The Roche Merger Will Do Wonders for Spark Stock.NEWS11: Ligand Sells Promacta Rights for $827M, Updates '19 View.NEWS12: Ligand Sells Promacta Rights for $827M, Updates '19 View.NEWS13: Ligand Sells Promacta Rights for $827M, Updates '19 View.
2019-03-07: NEWS1: Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy.NEWS2: Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy.NEWS3: Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy.NEWS4: Alnylam Stock Down Despite Positive Phase III Givosiran Data.NEWS5: Alnylam Stock Down Despite Positive Phase III Givosiran Data.NEWS6: BMY and NVS: How Tax Rates and Interest Expenses Stack Up.NEWS7: How Novartis and BMY’s Dividend Profiles Stack Up.NEWS8: Alnylam Stock Down Despite Positive Phase III Givosiran Data.NEWS9: Pre-Market Most Active for Mar 7, 2019 :  ALT, KR, NIO, SQQQ, GE, AMD, QQQ, TVIX, ACB, NVS, EAF, PS.NEWS10: Pre-Market Most Active for Mar 7, 2019 :  ALT, KR, NIO, SQQQ, GE, AMD, QQQ, TVIX, ACB, NVS, EAF, PS.NEWS11: Novartis or BMY: Who’s Controlling Expenses Better?.

Answer: Rise